

NDAs: See Attached List

SUPPLEMENT APPROVAL

UCB, Inc.

Attention: Lara Duffney, PhD Regulatory Scientist 4000 Paramount Parkway Suite 200 Morrisville, NC 27560

Dear Dr. Duffney:

Please refer to your supplemental New Drug Application(s) (sNDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA), and all amendments, for the following products:

Supplemental Application	Product Information	Submit Date	FDA Received Date
NDA 022254/S-044	Vimpat (lacosamide)	November	November
	Injection	19, 2021	19, 2021
NDA 022253/S-054	Vimpat (lacosamide)	November	November
	Tablets	19, 2021	19, 2021
NDA 022255/S-036	Vimpat (lacosamide)	November	November
	Oral Solution	19, 2021	19, 2021

These "Changes Being Effected" supplemental new drug applications provide for an update to the "United States Prescribing Information" (USPI) in response to a CBE-0 Supplement Request regarding the ingredient statement for Vimpat Injection. Also, updates to the "USPI", Medication Guide, and Vimpat Injection carton labeling to include the quantity or function of two inactive ingredients present in Vimpat Injection.

## **APPROVAL & LABELING**

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(I)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <a href="http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm">http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm</a>. Content of labeling must be identical to the enclosed labeling (text for the prescribing

**U.S. Food & Drug Administration** 



NDAs: See Attached List

Page 2

information, and Medication Guide) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <a href="http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/GuidanceS/UCM072392.pdf">http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/GuidanceS/UCM072392.pdf</a>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **CARTON AND CONTAINER LABELS**

Submit final printed carton and container labels that are identical to carton and container labels submitted on May 17, 2022, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission "**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 022254/S-044.**" Approval of this submission by FDA is not required before the labeling is used.

## REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).



NDAs: See Attached List

Page 3

If you have any questions, call Avani Patel, Regulatory Business Process Manager, at (240) 402 - 1845.

Sincerely,


{See appended electronic signature page}

Gurpreet Gill-Sangha, Ph.D.
Branch Chief, Branch 3
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure:

Content of Labeling





Date: 5/19/2022 09:27:40AM

GUID: 5135f2ad000117842392c50c36c7f28a

